Profile data is unavailable for this security.
About the company
WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.
- Revenue in HKD (TTM)18.43bn
- Net income in HKD3.68bn
- Incorporated2014
- Employees12.74k
- LocationWuXi Biologics (Cayman) IncNo. 108, Meiliang Road, MashanWUXI ChinaCHN
- Websitehttps://www.wuxibiologics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 1.67bn | -621.06m | 30.58bn | 1.42k | -- | 12.13 | -- | 18.35 | -2.80 | -2.80 | 7.60 | 11.50 | -- | -- | -- | 1,177,674.00 | -- | -- | -- | -- | 49.28 | -- | -37.27 | -- | 2.47 | -34.90 | 0.0251 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| Akeso Inc | 4.90bn | 2.19bn | 38.40bn | 2.78k | 16.93 | 7.35 | 13.88 | 7.84 | 2.62 | 2.62 | 5.84 | 6.04 | 0.6168 | 0.3671 | 15.98 | 1,762,496.00 | 26.47 | -11.59 | 31.40 | -13.87 | 97.02 | -- | 42.91 | -42.49 | 4.39 | 62,663.10 | 0.3983 | -- | 440.35 | 337.43 | 273.60 | -- | -- | -- |
| Sino Biopharmaceutical Ltd | 28.34bn | 2.00bn | 47.76bn | 25.81k | 21.19 | 1.45 | 7.85 | 1.69 | 0.1199 | 0.1481 | 1.53 | 1.75 | 0.4104 | 2.31 | 5.73 | 1,098,228.00 | 7.23 | 13.29 | 13.37 | 22.05 | 80.95 | 79.78 | 17.61 | 27.26 | 0.9649 | 7.33 | 0.2479 | 24.88 | -8.97 | 4.63 | -27.38 | -27.22 | -- | 1.15 |
| WuXi Biologics (Cayman) Inc | 18.43bn | 3.68bn | 54.52bn | 12.74k | 15.32 | 1.25 | 10.17 | 2.96 | 0.8358 | 0.8358 | 4.24 | 10.25 | 0.321 | 5.04 | 2.85 | 1,446,357.00 | 6.73 | 8.28 | 8.47 | 10.25 | 40.08 | 43.25 | 20.96 | 27.46 | 2.54 | -- | 0.0939 | -- | 11.56 | 46.38 | -23.09 | 40.07 | -- | -- |
| Innovent Biologics Inc | 6.71bn | -1.11bn | 55.09bn | 4.87k | -- | 4.06 | 1,050.59 | 8.21 | -0.705 | -0.705 | 4.30 | 8.36 | 0.3248 | 0.9481 | 7.85 | 1,377,942.00 | -5.38 | -13.06 | -6.80 | -15.85 | 81.69 | 84.51 | -16.56 | -43.44 | 2.78 | -- | 0.2242 | -- | 36.21 | 265.79 | 52.83 | -- | -- | -- |
| CSPC Pharmaceutical Group Ltd | 34.02bn | 6.35bn | 71.54bn | 23.50k | 11.21 | 1.99 | 9.20 | 2.10 | 0.5351 | 0.5351 | 2.86 | 3.02 | 0.7144 | 3.26 | 6.31 | 1,447,691.00 | 13.79 | 16.08 | 18.50 | 21.57 | 70.51 | 72.95 | 19.31 | 19.63 | 2.32 | 26.52 | 0.0198 | 35.51 | 1.66 | 12.16 | -3.58 | 13.77 | -- | 25.33 |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Oct 2022 | 202.45m | 4.75% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 139.30m | 3.27% |
| E Fund Management Co., Ltd.as of 30 Jun 2023 | 123.14m | 2.89% |
| Schroder Investment Management Ltd.as of 29 Feb 2024 | 86.08m | 2.02% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 70.08m | 1.65% |
| BlackRock Fund Advisorsas of 25 Mar 2024 | 69.65m | 1.64% |
| Schroder Investment Management (Hong Kong) Ltd.as of 31 Dec 2023 | 55.88m | 1.31% |
| Invesco Advisers, Inc.as of 29 Feb 2024 | 51.91m | 1.22% |
| Hang Seng Investment Management Ltd.as of 03 Apr 2024 | 45.34m | 1.07% |
| BlackRock Advisors (UK) Ltd.as of 25 Mar 2024 | 45.16m | 1.06% |
